Immatics N.V. - Ordinary Shares (NQ:IMTX)

10.41 -0.25 (-2.35%)

Streaming Delayed Price Updated: 12:39 PM EDT, Apr 10, 2026 Add to My Watchlist

Price and Volume

Volume	73,324
Open	10.73
Bid (Size)	10.41 (100)
Ask (Size)	10.44 (200)
Prev. Close	10.66
Today's Range	10.41 - 10.73
52wk Range	3.450 - 12.41
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Immatics Announces Full Year 2025 Financial Results and Business Update

March 05, 2026

From https://immatics.com/

Via GlobeNewswire

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

December 11, 2025

From https://immatics.com/

Via GlobeNewswire

Performance

YTD	-0.4%	-0.4%
1 Month	-0.9%	-0.9%
3 Month	+11.7%	+11.7%
6 Month	-4.5%	-4.5%
1 Year	+157.7%	+157.7%

More News

Immatics Announces $125 Million Underwritten Offering

December 05, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Appoints Amie Krause as Chief People Officer

October 27, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Appoints Venkat Ramanan as Chief Financial Officer

October 01, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Third Quarter 2025 Financial Results and Business Update

November 17, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

November 12, 2025

From https://immatics.com/

Via GlobeNewswire

Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures

October 20, 2025

Via MarketMinute

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

October 20, 2025

From https://immatics.com/

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 02, 2025

Via Benzinga

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

August 19, 2025

Via Benzinga

Immatics Announces Second Quarter 2025 Financial Results and Business Update

August 13, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

May 31, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces First Quarter 2025 Financial Results and Business Update

May 13, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

April 23, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Full Year 2024 Financial Results and Business Update

March 27, 2025

From https://immatics.com/

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 03, 2025

Via Benzinga

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

November 18, 2024

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

November 08, 2024

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Pricing of $150 Million Public Offering

October 10, 2024

From https://immatics.com/

Via GlobeNewswire

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? ↗

October 10, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 10, 2024

Via Benzinga

Immatics Announces Proposed $150 Million Public Offering

October 10, 2024

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

October 10, 2024

From https://immatics.com/

Via GlobeNewswire

Frequently Asked Questions

Is Immatics N.V. - Ordinary Shares publicly traded?

Yes, Immatics N.V. - Ordinary Shares is publicly traded.

What exchange does Immatics N.V. - Ordinary Shares trade on?

Immatics N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Immatics N.V. - Ordinary Shares?

The ticker symbol for Immatics N.V. - Ordinary Shares is IMTX on the Nasdaq Stock Market

What is the current price of Immatics N.V. - Ordinary Shares?

The current price of Immatics N.V. - Ordinary Shares is 10.41

When was Immatics N.V. - Ordinary Shares last traded?

The last trade of Immatics N.V. - Ordinary Shares was at 04/10/26 12:39 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.